Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096728 · ClinicalTrials.gov registry record
Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)
A clinical trial of Preeclampsia With Severe Features, sponsored by Ohio State University.
- Completed
- Registry status
- 56
- Enrollment target
- 1
- Study location
NCT05096728: Completed study of Preeclampsia With Severe Features, sponsored by Ohio State University.
NCT05096728 is a study of Preeclampsia With Severe Features that has completed, run by Ohio State University. The registered enrollment target is 56 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05096728, a study of Preeclampsia With Severe Features, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose a randomized controlled unblinded trial to evaluate rates of optimal blood pressure control between Nifedipine 60mg XL once daily vs. Nifedipine 30mg XL twice daily in patients admitted for expectant management with pre-eclampsia with severe features. Patients will be approached for consent when they are placed on 30mg of Nifedipine daily by their primary provider and will be enrolled in the study when the primary provider has made the decision to increase the patient's daily dose of Nifedipine XL from 30mg to 60mg.
Primary Outcome
Comparing the rates of suboptimal blood pressure, defined as frequency of systolic \>150 mmHg and/or diastolic \>100 mmHg blood pressure. Blood pressure measurements will be measured every 4 hours on day 2 (24 hour-48 hour) after the patient has been enrolled, randomized, and initiated on either once daily Nifedipine XL 60mg or twice daily Nifedipine XL 30mg.
Conditions Studied
Interventions
- DRUG Nifedipine XL
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2023-12-15 |
What the finished NCT05096728 record still lists
NCT05096728 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 56 participants, a relatively small participant target.
The record links to 1 condition, with Preeclampsia With Severe Features appearing as the primary indexed condition, and to 1 intervention - of which Nifedipine XL is the first listed.
NCT05096728 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05096728 about?
NCT05096728 is a clinical study titled "Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)". The investigators propose a randomized controlled unblinded trial to evaluate rates of optimal blood pressure control between Nifedipine 60mg XL once daily vs. Nifedipine 30mg XL twice daily in patients admitted for expectant management with pre-eclampsia with severe features. Patients will be appro...
What is the current status of trial NCT05096728?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2021-12-01. Estimated completion is 2023-12-15.
What conditions does trial NCT05096728 study?
This clinical trial studies the following conditions: Preeclampsia With Severe Features.
What interventions are being tested in trial NCT05096728?
The interventions under investigation include: Nifedipine XL (DRUG).
Who is sponsoring clinical trial NCT05096728?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05096728 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI